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Purpose/Objective: In October and November 2014 a 
dosimetric audit of IMRT and VMAT was carried out for 2 
radiation oncology institutes in the Netherlands. The final 
goal is to have audited all Dutch institutes by mid April 2015. 
For a limited set of RT plans, defined by the audit 
committee, the dose distribution computed by an institution's 
treatment planning system is compared with the dose 
measurements performed by the audit team at the 
institution's linear accelerators. This is done independently 
from the treatment planning optimization process. 
Additionally, the results are compared to the QA 
measurements done by each institute according to their local 
protocol.  
Materials and Methods: A simple and a complex IMRT plan 
and a simple, a complex and a stereotactic treatment VMAT 
plan were created for all linac models in use in the 
Netherlands and imported in treatment planning systems 
employed by the participating institutes. Each plan was 
measured by an ionization chamber (pinpoint), Gafchromic 
film and a 2D ionization chamber array (Octavius, PTW). 
Differences between the measured and computed 2D dose 
distributions were investigated by a gamma analysis with a 
5%,1mm criterion for the stereotactic treatment plan and 
3%,3mm for the other plans. Additionally, the participating 
centers performed QA measurements of the same treatment 
plans according to their local protocol.  
Results: For the first 2 institutions results showed an 
agreement for the dose point measurements within 2 % for 
the investigated plans. The gamma analysis had a passing 
rate higher than 98% for all the plans. These findings 
compared well with the QA measurement results reported by 
the institutions according to their local protocols.  
Final results will follow in April 2015 when all the institutes 
will be audited.  
Conclusions: The preliminary results demonstrate that such a 
national QA audit is feasible. Importing and computing the 
prepared treatment plans in the planning systems in use in 
the country is achievable.  
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Purpose/Objective: To investigate the feasibility of using low 
cost commercially available glass beads as thermo-
luminescence dosimeters (TLD) for postal dosimetry audit. 
The UK SABR Lung Consortium dosimetry audit was designed 
to assess the positional and dosimetric accuracy of SABR lung 
treatment delivery. This was achieved with the use of 
Alanine pellets and EBT3 GafChromic film, placed in a CIRS 
thorax phantom. In conjunction with this audit, 20 volunteer 
centres also assessed the feasibility of using glass bead TLDs 
for a postal dosimetry audit.  
Materials and Methods: Commercially available glass beads 
with a size of 1 mm thickness and 1.5 mm diameter, 
dosimetrically characterized as TLDs [1-3], were used for a 
postal dosimetry audit of SABR lung treatment, with the glass 
beads cross calibrated against the alanine dosimeters in 
reference conditions. A CT scan of a CIRS anthropomorphic 
thorax phantom, with 1.25 mm slice spacing and thickness 
was used to pre-delineate volumes relating to the Internal 
Target Volume (ITV) and alanine pellets. This CT scan and 
volume set was sent to the centres and was loaded into their 
treatment planning system (TPS) to create a SABR plan using 
their current planning protocols and techniques. The glass 
beads were held in an insert which was designed to 
externally match that of the alanine holder. The central axis 
of the glass beads was positioned to match that of the 
alanine pellets, and giving the same measurement length. 
During the audit a second irradiation was made to the glass 
beads and the doses determined by the glass beads were 
compared to those measured by alanine, the local ionisation 
chamber, film and the expected doses determined by TPS 
calculation.  
Results: The mean percentage difference between the 
measured doses by the glass beads and the local chamber, 
alanine and film measurements and calculated doses by the 
TPS, are given in figure 1. The mean % difference between 
the measured doses by the glass beads and the calculated 
doses by the TPS was found to be 0.7% (SD=2.0) and differed 
by 0.6% (±1.5), 1.3 % (±1.4) and 0.7 % (±2.3) from alanine, 
local ion chamber and film measurements respectively.  
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Conclusions: Results obtained with the glass beads agree 
with those obtained from conventional detectors including 
alanine, film and ionisation chambers. This together with the 
waterproof characteristics and minimal fading associated 
with glass bead TLDs confirm their potential as a postal 
dosimetry audit tool. 
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Purpose/Objective: For small radiation fields, the 
uncertainty in dose measurement is higher than for 
conventional radiotherapy fields (Castro 2008). To address 
this, manufacturers have custom designed dosimeters 
specifically for this niche physical treatment condition. 
Several types of small field dosimeters, although convenient, 
still need small field correction factors [SFCF] to achieve a 
valid measure of dose. The aim of this work is to quantify the 
performance of a range of specialized small field dosimeters 
and to show the effect of incorrect application of SFCFs. This 
is done by calculating the result of propagating these errors 
through treatment. 
Materials and Methods: Two sample patient treatments are 
considered: the first case a trigeminal neuralgia and the 
second a brain metastasis. Each patient plan is evaluated 
using the smallest 4mm BrainLAB cone on a Varian Novalis 
linear accelerator. For each case the plan was calculated 
using measured data made with the following small field 
dosimeters: IBA SFD, PTW 60012, PTW microdiamond, 
Australian Air-core dosimeter, Standard Imaging Exradin and 
Gafchromic EBT film. 
Results/ The diodes and the microdiamond were found to 
over-respond. The dose delivered was found to be up to 10% 
less than that prescribed to the target volume, depending on 
the dosimeter used to commission the planning system and 
whether SFCF and volume averaging corrections are applied. 
For small fields, the scintillation dosimeters and film 
required only correction for volume averaging, minimizing 
dosimetric uncertainties. 
Conclusions: A specific patient prescription is tailored to 
account for the individual patient’s needs. However once a 
prescription is made, it should be delivered as accurately as 
possible, irrespective of whether it is a small or large 
treatment field. There is an accepted variability in 
prescriptions for the treatment of brain lesions with small 
fields (e.g. trigeminal neuralgia and brain metastasis), which 
may be attributed in part to the present variability in small 
field dosimetry. Two prescriptions may be delivering the 
same dose, but the dosimetry may be reporting it as 
different. Since clinical response has been used to determine 
the dose prescription protocols, solutions to the challenges of 
small field dosimetry should be agreed upon.  
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Purpose/Objective: To investigate the variability of the 
global gamma index analysis in various commercial 
IMRT/VMAT (Intensity Modulated Radiation Therapy/ 
Volumetric Arc Therapy) Quality Assurance (QA) systems. In 
addition, this study evaluates the relationship of these 
gamma analysis results and clinical dose volume histogram 
(DVH) for VMAT treatment plans and to understand how 
systematic VMAT multileaf collimator (MLC) positional errors 
affect the patient dose distribution. 
Materials and Methods: Five commercial QA systems (IBA 
MatriXX, SunNuclear ArcCHECK, PTW 2D-Array, Varian EPID, 
and Gafchromic EBT2 film) were used for defining the global 
gamma index variability in IMRT /VMAT plans and two of QA 
systems (IBA MatriXX and SunNuclear ArcCHECK) and their 
commercial QA system software (IBA-COMPASS and 
ArcCHECK- 3DVH) were used to evaluate the relationship of 
these gamma analysis results and DVH in VMAT plans. Five 
prostate plans (two IMRT and three VMAT) and five larenks 
plans (two IMRT and three VMAT ) were modified by the 
introduction of systematic MLC errors and were evaluated in 
each sytem. Systematic MLC errors were simulated for error 
magnitudes of 0.25, 0.5, 1, 2 and 5 mm. The two types of 
systematic MLC errors were: (1) MLC banks are shifted in the 
same direction (left or right) and (2) MLC banks are shifted in 
opposing directions resulting in smaller or larger field shapes. 
Error-induced plans were measured on a linear accelerator 
and were evaluated against the error-free dose distribution 
calculated using Varian Eclipse treatment planning system in 
the relevant phantom CT scan. A theoretical gamma analysis 
was calculated in each commercial QA system software (IBA 
OmniPro, SNC Patient, PTW Verisoft,Varian Portal Dosimetry 
and IBA OmniPro, respectively) using treatment planning 
system. For evaluating the relationship of the gamma analysis 
and DVH, all QA verification plans were delivered and 
estimated 3D patient dose on the 3DVH and COMPASS 
software. QA gamma analysis of 3%/3 mm and 2%/2 mm were 
implemented and relationships to dose differences in DVH 
metrics encountered due to MLC errors were determined. 
Results: The 2 mm systematic errors were difficult to detect 
using 3%/3 mm but were detectable for criteria of 2%/2 mm. 
This study has shown that various commercial software agree 
well with each other in calculating the predicted global 
gamma index passing at even tight passing criteria of 2%/2 
mm. There is lack of consistently strong correlation between 
gamma indexes and clinical DVH metrics for PTV and OARs. 
Conclusions: There was considerable variation in the type of 
errors that the various systems detected. It was also found 
that the calibration and measuring procedure could benefit 
from improvements for some of the patient QA. 
    
 
 
 
 
 
